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Therapeutic Misconception and 
Misdirection 
Therapeutic Misconception 
 An unfounded belief held 
by a research participant 
that he or she will be 
receiving personalized 
care.  Often accompanied 
by an unrealistic 
expectation of benefit. 
 
Research vs Practice 
 Practice 
 Goal is to further the best interest of the individual patient. 
 Patient-centered care, tailored to the individual. 
 Research 
 Goal is to generate new knowledge that may benefit future 
patients. 
 Protocol-driven care with little flexibility, designed to produce 
interpretable data and generalizable knowledge. 
Origin of TM 
 Fundamentally, a confusion between research and practice. 
 Both doctors (investigators) and patients (participants) are 
susceptible. 
 
Therapeutic Misconception in 
participants 
 Prevalence 
 31% expressed inaccurate beliefs regarding degree of 
individualization of their treatment. 
 51% expressed an unreasonable belief in the nature or 
likelihood of benefit. 
 Overall, 62% had one or both of the above. 
Applebaum, PS 2004, IRB: Ethics and Human Research 26:1 
Why worry about TM? 
 Participants that harbor TM 
are likely to: 
 Overestimate likely benefit 
 Underestimate risks 
 Be confused about 
randomization 
 Conflate research with 
ordinary treatment 
 
Therapeutic Misdirection 
 Physicians as “double agents” 
 Competing obligations that sometimes conflict 
 Physician: primary obligation is to the patient 
 Investigator: primary obligation is to the research 
What is Therapeutic Misdirection? 
 Actions taken by an investigator to try and reconcile the 
competing obligations of clinical medicine with clinical 
research. 
 Attempt to deliver personalized care in the context of a 
research protocol 
 Often requires deviating from the protocol 
 Promotes patient-participant TM 
 May compromise scientific validity of the study 
WU protocol exception requests 
 Examined all protocol exception in eIRB 2008-2011 
 Classified into one of 7 categories 
 Analyzed 
 Exception type 
 Department of requestor 
 Funding 
 Frequency per protocol 
 Types of protocols 
 Frequency per investigator 
 
Exception classifications 
Exception type Description 
Entry criteria Enrolling subjects that are ineligible according to inclusion/exclusion 
criteria 
Other entry enrolling subjects that would not otherwise be permitted to enroll, 
but not due to ineligibility according to I/E criteria 
Example: 
• Enrolling a non-english speaking person in a study not 
approved for non-english speaking persons 
• Utilizing an LAR for a study not approved to enroll cognitively 
impaired subjects. 
Out of window-testing Performing a test, either for enrollment purposes or during the trial, 
outside the protocol specified time window 
Out of window-
treatment 
performing a treatment or intervention (other than diagnostic 
testing) outside of the protocol specified time window 
Treatment participation 
exception 
altering a treatment intervention outside of what is in the approved 
protocol 
Examples: 
• Changing drug dosing or delivery 
• holding a drug, 
• Allowing a subject to continue treatment despite lab value 
that specifies holding treatment. 
Testing participation 
exception 
altering a research test intervention outside of what is in the 
approved protocol 
Examples: 
• not performing a scan or diagnostic test that is prescribed in 
the protocol. 
Other participation 
exception: 
Other changes to conduct of the study, that occur to the subject 
once already enrolled in the study, but not captured in above 
categories 
Results 
 1509 open protocols being conducted by 439 Principal 
Investigators during time period examined. 
 106 PI’s requested 312 exceptions in 177 separate protocols 
 11% of open protocols had an exception request 
 24% of Investigators requested at least 1 exception 
Distribution of exception types 
Frequency of exceptions and open 
protocols by Department 
 
Does funding matter? 
 
Frequency of exceptions per PI 
Number of 
Investigators 
Number of 
exception requests 
53 1 
18 2 
15 3 
5 4 
3 5 
3 6 
1 7 
2 8 
1 9 
1 10 
1 12 
1 15 
1 18 
1 38 
Exception frequency per protocol 
Number of Studies Number of exception 
requests 
119 1 
25 2 
15 3 
5 4 
5 5 
6 6 
1 7 
1 10 
 10 exceptions for 1 protocol 
 Phase 1 hematologic malignancy trial 
 Eligibility criteria – 8 
o Different disease 
o Labs out of range 
o Had prior excluded therapies 
 Out of window test-1 
 Other participation exception – 1 
 Reasons given by PI 
 “enable patient to receive treatment” 
 “combination treatment will offer patient a better outcome” 
 
Phase 1 trials 
Horstmann et al, 2005 NEJM 352:9  
 Overall Efficacy 
 CR+PR= 10.6% 
 CR=3.1%, PR=7.5%, SD + <PR=34.1% 
 Overall toxicity 
 Deaths 0.49% 
 Grade 4 toxicity 14.3% 
 
 Phase 1 trials 
 50 protocols (29%) 
 72 exception requests (23% of total)   
 Phase 2 trials 
 49 protocols (28%) 
 88 exception requests (28% of total)  
 Phase 3 trials 
 17 protocols (10%) 
 21 exception requests (7% of total) 
Prospect of benefit? 
 Exception requests in Phase 1 trials 
 38 -Eligibility criteria 
 7 – Out of window-testing 
 12 - Out of window-treatment 
 10 - Treatment participation exception 
 3 - Testing participation exception 
 2 - Other participation exception 
 23/38 indicated it would allow patient to have “treatment”. 
 7/38 state the patient will benefit by receiving the 
investigational drug. 
 
 
 
Why? 
 Competing obligations and inherent conflicts 
 Are we doctors trying desperately to treat a dying patient or 
investigators trying to determine if the drug is safe and 
effective? Can we do both at the same time? 
 Pressure to enroll and complete trials 
What’s the downside?  
 Effect on the science 
 At best it muddies the water, at worst, invalidates the data. 
 Effect on the patient-participant 
 Further promotes their own therapeutic misconception. 
 Effect on the investigator 
 Further blurs the distinction between roles and obligations 
 Potential to effect overall risk/benefit analysis of the study. 
Conclusions 
 Requests to deviate from the approved protocol are relatively 
frequent among protocols and investigators 
 Protocol deviations are a reasonable way to measure therapeutic 
misdirection 
 Exceptions are not limited to trials in which the drug has 
evidence of safety and efficacy. 
 Physician expectation of benefit is common in requesting an 
exception 
 Physicians attempt to use established trials as a mechanism 
for “expanded access” 
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